Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. [electronic resource]
Producer: 20080523Description: 1561-70 p. digitalISSN:- 1078-0432
- Antibodies, Monoclonal -- pharmacology
- Antibodies, Monoclonal, Murine-Derived
- Antibody-Dependent Cell Cytotoxicity
- Antigens, CD20 -- genetics
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Biomarkers, Tumor -- genetics
- Blotting, Northern
- Blotting, Western
- Boronic Acids -- pharmacology
- Bortezomib
- Calcium -- metabolism
- Down-Regulation
- Drug Resistance, Neoplasm
- Flow Cytometry
- Gene Expression Profiling
- Humans
- Immunoglobulins -- metabolism
- Lymphoma, B-Cell -- drug therapy
- Membrane Microdomains -- drug effects
- Oligonucleotide Array Sequence Analysis
- Phenotype
- Protease Inhibitors -- pharmacology
- Proteasome Inhibitors
- Pyrazines -- pharmacology
- RNA, Messenger -- genetics
- Reverse Transcriptase Polymerase Chain Reaction
- Rituximab
- Transcription, Genetic -- drug effects
- Tumor Cells, Cultured
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.